Microdosing Research: What Controlled Trials Actually Show
About This Video
A research-focused review of controlled microdosing trials, distinguishing between the large observational/self-report literature and the smaller controlled trial literature. The gap between the two is significant: self-report data shows substantial benefits; controlled trials show smaller or null effects in many domains.
The Imperial College London 2024 Fadiman Protocol RCT is covered in detail — the study that put the most widely-used microdosing protocol into a rigorous controlled design. Results were more modest than the self-report literature suggests, particularly for cognitive enhancement claims.
The expectation effects problem in microdosing research is discussed honestly: blinding is difficult at any active dose, meaning participants may know they received the active drug, inflating self-reported outcomes. This doesn't mean microdosing doesn't work — it means we need better study designs to separate real effects from expectation.
Key Takeaways
- Self-report microdosing data suggests broad benefits; controlled trials show smaller, more domain-specific effects.
- The Imperial College 2024 RCT found mood benefits but did not replicate strong cognitive enhancement claims.
- Blinding is a fundamental challenge: participants often know they received active drug, inflating self-reported outcomes.
- For sub-clinical depression and low mood, controlled data is most supportive; cognitive enhancement claims remain unproven in controlled conditions.
- The Fadiman Protocol (1 day on, 2 days off) is the most studied; tolerance develops and breaks are recommended.
Dive Deeper
Continue exploring this topic on LearnShrooms: